Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab Plus Docetaxel in Advanced Non-small-cell Lung Cancer
NCT00983047Phase 2Terminated
- Start
- Aug 2009
- Primary completion
- Aug 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in non-small cell lung cancer (NSCLC). Started Aug 2009; status: terminated.
02
Drugs
nimotuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00983047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00983047.